Premium
New antidepressants and 5‐HT uptake inhibitors
Author(s) -
Montgomery S.A.
Publication year - 1989
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1989.tb07187.x
Subject(s) - tricyclic , paroxetine , depression (economics) , placebo , antidepressant , medicine , reuptake inhibitor , psychiatry , psychology , pharmacology , anxiety , alternative medicine , macroeconomics , pathology , economics
The efficacy of 5‐HT uptake inhibitors, including paroxetine, as antidepressants is compared with that of the reference tricyclic antidepressants. It is suggested that some of the older tricyclicantidepressants might not have been released for general clinical use if tested by today's rigorous standards. Placebo‐ controlled, multicentre studies indicate that 5‐HT uptake inhibitors are both effective as antidepressants and well tolerated by depressed patients. They also appear to have a role in the treatment of depression when associated with personality disorders, in the treatment of obsessive‐compulsive disorder and bulimia, and in resistant depression. Moreover, the evidence for efficacy in the prophylaxis of depression is better established for 5‐HT uptake inhibitors than for reference antidepressants.